Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice
The Journal of Immunology · 2023
DOI: 10.4049/jimmunol.2200550 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2023. Verfasst von Benedikt Kaufmann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California San Diego, La Jolla, CA. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Cryopyrin-Associated Periodic Syndromes. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: NIDDK NIH HHS, NIAAA NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
Antisense oligonucleotides (ASOs) are a novel therapeutic strategy that targets a specific gene and suppresses its expression. The cryopyrin-associated periodic syndromes (CAPS) are a spectrum of autoinflammatory diseases characterized by systemic and tissue inflammation that is caused by heterozygous gain-of-function mutations in the nucleotide-binding and oligomerization domain-like receptor (NLR) family pyrin domain containing 3 (NLRP3) gene. The aim of this study was to investigate the efficacy of an Nlrp3-specific ASO treatment in CAPS. An Nlrp3-specific ASO was designed and tested in murine cell lines and bone marrow–derived macrophages (BMDMs) from wild-type and CAPS mouse models. Nlrp3 knock-in mice were treated in vivo with Nlrp3-specific ASO, survival was monitored, and expression of organ-specific Nlrp3 and IL-1β was measured. Nlrp3-specific ASO treatment of murine cell lines and BMDMs showed a significant downregulation of Nlrp3 and mature IL-1β protein expression. Ex vivo treatment of Nlrp3 mutant mouse-derived BMDMs with Nlrp3-specific ASO demonstrated significantly reduced IL-1β release. In vivo, Nlrp3-specific ASO treatment of Nlrp3 mutant mice prolonged survival, reduced systemic inflammation, and decreased tissue-specific expression of Nlrp3 and mature IL-1β protein. The results of this study demonstrate that Nlrp3-specific ASO treatment downregulates Nlrp3 expression and IL-1β release in CAPS models, suggesting ASO therapy as a potential treatment of CAPS and other NLRP3-mediated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of California San Diego, La Jolla, CA.
- Klinik und Poliklinik für Chirurgie, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
- Secarna Pharmaceuticals GmbH & Co. KG, Planegg/Martinsried, Germany.
- Rady Children's Hospital-San Diego, San Diego, CA.
ORCID-Profile: Janset Onyuru, Sven Michel, Richard Klar, Lori Broderick
Förderung
- NIDDK NIH HHS
- NIAAA NIH HHS
- HHS | National Institutes of Health
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Kaufmann, B., de Los Reyes Jiménez, M., Booshehri, L. M., Onyuru, J., Leszczynska, A., Uri, A., Michel, S., Klar, R., Jaschinski, F., Feldstein, A. E., Broderick, L., & Hoffman, H. M. (2023). Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2200550
Vancouver
Kaufmann B, de Los Reyes Jiménez M, Booshehri LM, Onyuru J, Leszczynska A, Uri A, et al. Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2200550
BibTeX
@article{Kaufmann2023,
author = {Kaufmann, Benedikt and de Los Reyes Jiménez, Marta and Booshehri, Laela M and Onyuru, Janset and Leszczynska, Aleksandra and Uri, Anna and Michel, Sven and Klar, Richard and Jaschinski, Frank and Feldstein, Ariel E and Broderick, Lori and Hoffman, Hal M},
title = {Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice},
journal = {The Journal of Immunology},
year = {2023},
doi = {10.4049/jimmunol.2200550}
}
EUVIMED